Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Rank in Stocks #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behรงet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Share Price
$263.38
Market Cap
$465.34B
Change (1 day)
-0.63%
Change (1 year)
18.33%
Country
US
Trade AbbVie Inc. (ABBV)

Category

Earnings for AbbVie Inc. (ABBV)
Earnings in Jun 2026 TTM: $8.70B
According to AbbVie Inc. latest financial reports the company's current earnings are $8.70B. In 2024 the company made an earning of $3.72B, a decrease compared to its 2023 earnings that were of $6.25B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for AbbVie Inc. from 2009 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $8.70B 31.86%
2025 $6.60B 77.53%
2024 $3.72B -40.54%
2023 $6.25B -53.62%
2022 $13.48B 3.76%
2021 $12.99B 282.25%
2020 $3.40B -59.67%
2019 $8.43B 62.13%
2018 $5.20B -32.74%
2017 $7.73B -1.99%
2016 $7.88B 18.65%
2015 $6.65B 180.50%
2014 $2.37B -55.57%
2013 $5.33B -6.86%
2012 $5.73B 56.08%
2011 $3.67B -24.15%
2010 $4.84B -18.73%
2009 $5.95B 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$33.60B 286.20%
US
$25.20B 189.64%
US
$21.39B 145.87%
CH
$5.95B -31.62%
US
$16.38B 88.28%
CH